Suboptimal Adherence to Hereditary Cancer Risk Management Guidelines: A Cohort Study of High-Risk Individuals in Newfoundland and Labrador, Canada
Authors:
- Holly EtchegaryHEHolly Etchegary
- Rebecca PuddesterRPRebecca Puddester
- Zhiwei GaoZGZhiwei Gao
- Vanessa FrancisVFVanessa Francis
- Mike WarrenMWMike Warren
- T. Nadine BurryTBT. Nadine Burry
- Melanie SealMSMelanie Seal
- Michael WoodsMWMichael Woods
- Kathy WatkinsKWKathy Watkins
- April PikeAPApril Pike
- Susan AverySASusan Avery
- Jerry McGrathJMJerry McGrath
Open Access
- 26 March 2026
- journal article
- research article
- Published by MDPI AG in Current Oncology
- Vol. 33 (4) , 184
Abstract
Hereditary cancer syndromes (HCSs), including BRCA 1/2-associated hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS), confer substantial lifetime cancer risks, yet adherence to recommended risk-management strategies remains variable. This population-based retrospective cohort study examined cancer prevention practices, outcomes, and predictors of cancer occurrence among 476 BRCA and LS carriers identified through the Provincial Medical Genetics Program in Newfoundland and Labrador, Canada (2001–2022). Linked genetic, surgical, screening, and cancer registry data were evaluated, with adherence assessed during two intervals (2018–2020 and 2020–2022) based on NCCN guidelines. Participants were predominantly female (69%), with a mean age of 48.5 years at genetic testing; nearly 70% of primary cancers were already diagnosed at the time of testing. BRCA carriers demonstrated higher uptake of breast MRI (58–61%) and risk-reducing salpingo-oophorectomy (63–66%) compared with LS carriers’ colonoscopy uptake (42–44%). In univariate analyses, non-adherence during 2018–2020 was associated with increased odds of cancer after testing (OR ≈ 4.43, p < 0.001); this remained significant in the multivariate model (OR = 8.70; p = 0.0004). Individuals who did not follow recommended risk-management guidelines had nearly nine times greater odds of developing cancer after genetic testing than those who fully adhered to guidelines. Older age at referral (OR = 1.07/year, p < 0.001) also increased the odds of developing cancer. Study findings indicate that late referral and pre-existing cancers diminish the preventive impact of guideline-based risk management. System-level initiatives to promote earlier genetic testing, enhance cascade outreach, and strengthen surveillance pathways are needed to optimize cancer prevention and earlier cancer detection in high-risk populations.Keywords
Funding Information
- Canadian Institutes of Health Research https://ror.org/01gavpb45 (#179835)
This publication has 58 references indexed in Scilit:
- Association between cancer screenings uptake and genetic testing for cancer risk among US adults: findings from HINTS 2017–2020Journal of Community Genetics, 2025
- Barriers and facilitators to colonoscopy participation for colorectal cancer screening: a rapid reviewJournal of Public Health, 2025
- Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategyFamilial Cancer, 2024
- Cascade genetic testing: an underutilized pathway to equitable cancer care?Familial Cancer, 2024
- “There should be one spot that you can go:” BRCA mutation carriers’ perspectives on cancer risk management and a hereditary cancer registryJournal of Community Genetics, 2023
- Colonoscopy surveillance in Lynch syndrome is burdensome and frequently delayedFamilial Cancer, 2023
- Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysisCancer, 2021
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Adherence to Recommended Risk Management among Unaffected Women with a BRCA MutationJournal of Genetic Counseling, 2016
- Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)International Journal of Cancer, 2015